Utilization Review

Utilization review is the process health plans use to assess whether a medical service is medically necessary and appropriate — before, during, or after it's provided.

What Is Utilization Review?

Utilization review (UR) is the clinical evaluation behind utilization management (UM). A clinical reviewer — typically a nurse or physician — checks a requested or delivered service against evidence-based criteria to determine medical necessity and appropriate level of care.

It takes three forms:

• Prospective review — before the service, closely tied to prior authorization
• Concurrent review — during an ongoing stay or treatment
• Retrospective review — after the fact, often as part of a claims audit

UR is the mechanism. UM is the broader program it operates within.

Why Does UR Sit at the Center of Healthcare's Biggest Cost-Control Debate?

Consider the tension from both sides. Your plan uses UR to prevent unnecessary or low-value care from inflating costs. Meanwhile, physicians report the process itself delays necessary treatment and adds hours of administrative work — a friction point now drawing federal regulatory intervention.

Ninety-four percent of physicians report that prior authorization requirements — the most common form of prospective UR — delay patient care. Nearly seven in 10 insured adults describe the process as burdensome. (American Medical Association; KFF, 2025)

These aren't abstract numbers. A stalled review means a postponed treatment. A contested hospital stay mid-admission. A delivered service denied at the claim stage. Each carries measurable cost, clinical, and member-experience consequences that land directly on your operations.

How It Works

UR follows a consistent pattern across payers, even as criteria and timelines differ:

• Prospective review. A service request is evaluated against clinical criteria before delivery, most commonly through prior authorization.
• Concurrent review. An ongoing hospital stay or treatment course is reviewed in real time to confirm continued medical necessity — sometimes shortening or extending an authorized length of stay.
• Retrospective review. Care already delivered is reviewed after the fact, typically during a claims audit, to confirm it met medical necessity criteria for payment.
• Determination and appeal. The reviewer approves, denies, or requests additional information. Denials can generally be appealed with supporting clinical documentation.

A nurse reviewer typically conducts the initial evaluation against evidence-based criteria. Cases that don't clearly meet those criteria escalate to a physician reviewer — often in the same specialty as the requested service — for a final determination.

Utilization Review vs. Utilization Management

These terms get used interchangeably, but they describe different things.

UM is the broader program — encompassing prior authorization, case management, concurrent review, and retrospective review as a coordinated cost- and quality-control strategy. UR is the specific clinical evaluation activity within that program: the actual review of a request or delivered service against medical necessity criteria.

Every UR event happens inside a UM program, but UM includes activities — like case management for high-risk members — that extend beyond review alone. UR is a process. UM is the program built around it.

What Happens After a Denial

A denial isn't the end of the road. Providers or patients can generally appeal by submitting additional clinical documentation supporting medical necessity.

This matters because: for medical necessity denials with complete documentation, overturn rates commonly reach 70–83%. That gap between initial denial and eventual overturn signals something specific — documentation quality, not just clinical merit, often decides the outcome. If your review process generates high denial volumes that routinely get overturned on appeal, you're burning resources twice.

Why UR Is Under Regulatory Scrutiny

Physician and patient groups have raised concerns that UR — especially AI-assisted UR — is producing higher denial rates and delaying necessary care. CMS responded in 2024 by finalizing a rule requiring faster UR turnaround times and standardized reporting to increase transparency across Medicare Advantage, Medicaid, and Affordable Care Act (ACA) marketplace plans.

The regulatory direction is clear: shorter decision windows, public reporting of approval and denial rates, and tighter documentation requirements when AI is involved in the review. For your plan, that means UR is shifting from a largely internal cost-control lever to a publicly measured, audited discipline. Turnaround time, overturn rates, and denial reasoning are all becoming visible to regulators and members.

Path forward: Tighten your review workflows now. Align UR turnaround times with the new CMS benchmarks, audit your denial-to-overturn ratios, and ensure your documentation standards hold up under public scrutiny.

‍